STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

TG Therapeutics Rule 144 Notice: 20,852 Common Shares Proposed Sale

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

TG Therapeutics (TGTX) notice of proposed sale reports an insider intends to sell 20,852 common shares through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $672,232.59. These shares represent approximately 0.013% of the reported 158,665,613 shares outstanding and were acquired on 06/22/2023 by restricted stock vesting as compensation.

The filing lists no securities sold in the past three months and specifies the proposed sale date as 09/11/2025. The filer affirms they are not aware of any undisclosed material adverse information about the issuer. This is a routine Rule 144 disclosure showing a planned disposition of vested equity awarded as compensation.

Positive

  • Transparent disclosure of an insider sale pursuant to Rule 144 through Fidelity Brokerage Services
  • Securities were acquired via restricted stock vesting, indicating the shares originated from compensation rather than an open-market purchase
  • No other sales in the past three months reported for the selling person

Negative

  • None.

Insights

TL;DR: Small, routine Rule 144 sale by an insider; size is immaterial relative to outstanding shares.

The filing documents a planned sale of 20,852 shares valued at $672,232.59, acquired via restricted stock vesting on 06/22/2023. At roughly 0.013% of the companys stated outstanding shares, this transaction is unlikely to move market prices or significantly change ownership structure. The absence of other sales in the past three months and the filers statement about no undisclosed material information are consistent with routine insider liquidity events.

TL;DR: Filing shows standard compliance with disclosure rules; reflects transparency on insider compensation monetization.

The notice indicates the securities were awarded as compensation and vested on 06/22/2023, with the sale to be executed through Fidelity. Filing under Rule 144 notifies the market of an intended sale and helps maintain orderly disclosure. There are no indications in the form of accelerated sales, aggregated sales disclosures, or other governance red flags within the provided content.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for TGTX report?

The form reports a proposed sale of 20,852 common shares valued at $672,232.59 to be sold on 09/11/2025 through Fidelity on NASDAQ.

How were the shares acquired according to the filing?

The filing states the shares were acquired on 06/22/2023 through restricted stock vesting and were received as compensation.

What percentage of outstanding TGTX shares does this proposed sale represent?

The filing lists 158,665,613 shares outstanding; the proposed sale of 20,852 equals about 0.013% of outstanding shares.

Has the filer sold other TGTX securities in the past three months?

The form states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Through which broker will the sale be executed?

The notice names Fidelity Brokerage Services LLC as the broker handling the proposed sale.
Tg Therapeutics Inc

NASDAQ:TGTX

TGTX Rankings

TGTX Latest News

TGTX Latest SEC Filings

TGTX Stock Data

5.08B
147.99M
9.74%
64.63%
15.45%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK